Skip mediastinal lymph node metastasis in non-small cell lung cancer

Area of Science:

• Thoracic Oncology
• Surgical Pathology
• Cancer Metastasis Research

Background:

• N2 disease in non-small cell lung cancer (NSCLC) signifies metastasis to mediastinal lymph nodes.
• Skip metastasis, defined as N2 disease with negative N1 nodes, is a critical factor in NSCLC staging and prognosis.

Purpose of the Study:

• To investigate the incidence and significance of skip metastasis in patients with N2 non-small cell lung cancer.
• To analyze the impact of skip metastasis location on survival outcomes in NSCLC.

Main Methods:

• Retrospective analysis of 186 non-small cell lung cancer cases with N2 disease.
• Evaluation of skip metastasis incidence based on histology, T status, M status, and metastatic site.
• Comparison of 5-year survival rates between patients with and without skip metastasis, and by specific mediastinal lymph node regions.

Main Results:

• Skip metastasis was identified in 33% of N2 NSCLC patients.
• The incidence of skip metastasis did not significantly differ by histology, T, or M status.
• Mediastinal involvement of the aortic region alone showed a trend towards better prognosis (5-year survival 50%) compared to other regions, though not statistically significant.

Conclusions:

• Skip metastasis is frequent in N2 non-small cell lung cancer.
• Complete dissection of hilar and mediastinal lymph nodes is recommended in standard NSCLC operations due to the high incidence of skip metastasis.
• Aortic region involvement as the sole site of mediastinal metastasis may warrant further investigation for prognostic implications.